EU OKs $5.2B Watson-Actavis Tie-Up
The European Commission on Friday approved Watson Pharmaceuticals Inc.'s proposed €4.25 billion ($5.2 billion) acquisition of Swiss drugmaker Actavis Group, finding that the merged company will still face a significant number...To view the full article, register now.
Already a subscriber? Click here to view full article